Copy to clipboard 
Colson Medical announces Hjalmar Pompe van Meerdervoort as President of Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.
Pompe van Meerdervoort brings extensive global healthcare experience with his more than 25-year career in orthopedics and medical devices. Most recently, he was Senior Vice President and General Manager, Reconstruction at Smith+Nephew where he led the commercial functions for Smith+Nephew’s reconstructive joint portfolio.
Prior to Smith+Nephew, Pompe van Meerdervoort served as co-founder and CEO of VisionScope Technologies, an office-based arthroscopic imaging company. He was also Vice President and General Manager, Knees, at Zimmer, where he managed the company’s $2 billion flagship segment. He spent more than 10 years of his early career at Stryker growing his responsibility and reach to include international assignments.
“Over the past few months, we have conducted an extensive search to select the next leader of Acumed,” said Chris J. Smith, President, Colson Medical. “With his exceptional track record of leading teams and businesses to achieve superior results, we believe Hjalmar is the ideal President to lead Acumed in its next chapter of growth and success.”
Wolfington will transition into a new advisory role at Colson Medical, focused on key areas including thought leader management, business development and clinical research strategy. During her tenure at Acumed, the company merged with OsteoMed, with the combined business covering the hand, upper extremity, foot and ankle, trauma, craniomaxillofacial and sports medicine markets.
ORTHOWORLD estimates Acumed’s 2021 revenue at $460.5 million, an increase of 5.3% vs. 2020.
“We thank Sharon for her many contributions to Acumed. She has provided leadership to establish a robust innovation pipeline and deliver excellence to our customers through education, evidence, innovation, and quality,” said Smith. “We are pleased Sharon will continue with Colson Medical in service to the global medical community.”
Source: Acumed
Colson Medical announces Hjalmar Pompe van Meerdervoort as President of Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.
Pompe van Meerdervoort...
Colson Medical announces Hjalmar Pompe van Meerdervoort as President of Acumed, effective June 1. Pompe van Meerdervoort succeeds Sharon Wolfington, who will transition into a new advisory role for Colson Medical. After nearly five years at Acumed, Wolfington chose to pursue other professional and personal opportunities.
Pompe van Meerdervoort brings extensive global healthcare experience with his more than 25-year career in orthopedics and medical devices. Most recently, he was Senior Vice President and General Manager, Reconstruction at Smith+Nephew where he led the commercial functions for Smith+Nephew’s reconstructive joint portfolio.
Prior to Smith+Nephew, Pompe van Meerdervoort served as co-founder and CEO of VisionScope Technologies, an office-based arthroscopic imaging company. He was also Vice President and General Manager, Knees, at Zimmer, where he managed the company’s $2 billion flagship segment. He spent more than 10 years of his early career at Stryker growing his responsibility and reach to include international assignments.
“Over the past few months, we have conducted an extensive search to select the next leader of Acumed,” said Chris J. Smith, President, Colson Medical. “With his exceptional track record of leading teams and businesses to achieve superior results, we believe Hjalmar is the ideal President to lead Acumed in its next chapter of growth and success.”
Wolfington will transition into a new advisory role at Colson Medical, focused on key areas including thought leader management, business development and clinical research strategy. During her tenure at Acumed, the company merged with OsteoMed, with the combined business covering the hand, upper extremity, foot and ankle, trauma, craniomaxillofacial and sports medicine markets.
ORTHOWORLD estimates Acumed’s 2021 revenue at $460.5 million, an increase of 5.3% vs. 2020.
“We thank Sharon for her many contributions to Acumed. She has provided leadership to establish a robust innovation pipeline and deliver excellence to our customers through education, evidence, innovation, and quality,” said Smith. “We are pleased Sharon will continue with Colson Medical in service to the global medical community.”
Source: Acumed
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
